O1-7-5 - Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab

Abstract

Interstitial lung disease (ILD) has been known as an adverse event of EGFR-targeted therapy. For head and neck squamous cell cancer (HNSCC), anti-EGFR antibody cetuximab has been approved, but incidences and risk factors of ILD in HNSCC patients with cetuximab-containing treatment have not been established yet. We retrospectively reviewed the clinical records of HNSCC patients who received cetuximab-containing therapies from December 2012 to December 2016 in our institute; among them, patients who experienced ILDs were extracted and the details of their prognoses were investigated, and the incidence and risk factors of ILD were also evaluated. Total of 201 HNSCC patients were enrolled; in total 224 cetuximab-containing regimens were administered (cetuximab monotherapy = 10, combination with paclitaxel = 92, EXTREME regimen = 62, combination with platinum and taxane other than EXTREME = 5, combination with radiation = 55). During their treatment sequences, ILD was observed in 9 patients (4.5%); 8 of them were G3 or more, and 1 patient died of ILD. By the logistic regression analyses, high KL-6 (odds ratio = 20.1, 95% CI 4.39-91.9, p = 0.00011) and smoking index 1,000 or more (odds ratio = 4.7, 95% CI 1.03-21.1, p = 0.046) at baseline were predictive of ILD occurrence significantly. Incidence of ILD in cetuximab-containing treatment to HNSCC patients were less than 5%, but most of them were severe. High KL-6 and smoking index might be predictive for ILD for HNSCC.